See more : Godex International Co., Ltd (4987.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of BioAtla, Inc. (BCAB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioAtla, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Mobile Lads Corp. (MOBO) Income Statement Analysis – Financial Results
- JEENA SIKHO LIFECA (JSLL-ST.NS) Income Statement Analysis – Financial Results
- Sweet Earth Holdings Corporation (SEHCF) Income Statement Analysis – Financial Results
- Zoom Video Communications, Inc. (0A1O.L) Income Statement Analysis – Financial Results
- GLG Life Tech Corporation (GLGLF) Income Statement Analysis – Financial Results
BioAtla, Inc. (BCAB)
About BioAtla, Inc.
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 250.00K | 429.00K | 5.20M | 10.63M |
| Cost of Revenue | 103.73M | 1.20M | 1.33M | 19.93K | 25.92K | 26.31M |
| Gross Profit | -103.73M | -1.20M | -1.08M | 409.07K | 5.17M | -15.68M |
| Gross Profit Ratio | 0.00% | 0.00% | -432.00% | 95.35% | 99.50% | -147.53% |
| Research & Development | 103.73M | 79.35M | 58.27M | 19.93M | 25.92M | 26.31M |
| General & Administrative | 25.96M | 28.79M | 38.42M | 10.60M | 7.55M | 12.56M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 25.96M | 28.79M | 38.42M | 10.60M | 7.55M | 12.56M |
| Other Expenses | 0.00 | 10.00K | 1.00K | -1.00K | -22.00K | -5.00K |
| Operating Expenses | 129.69M | 108.14M | 96.69M | 30.53M | 33.47M | 38.86M |
| Cost & Expenses | 129.69M | 108.14M | 96.69M | 30.53M | 33.47M | 38.86M |
| Interest Income | 6.31M | 1.65M | 350.00K | 100.00K | 128.00K | 209.00K |
| Interest Expense | 0.00 | 3.00K | 1.39M | 1.63M | 949.00K | |
| Depreciation & Amortization | 1.22M | 1.20M | 1.33M | 1.01M | 860.00K | 794.00K |
| EBITDA | -122.24M | -106.48M | -94.07M | -33.46M | -27.37M | -27.24M |
| EBITDA Ratio | 0.00% | 0.00% | -37,903.60% | -6,758.04% | -525.04% | -256.29% |
| Operating Income | -129.69M | -108.14M | -96.44M | -30.10M | -28.27M | -28.23M |
| Operating Income Ratio | 0.00% | 0.00% | -38,576.00% | -7,016.08% | -543.62% | -265.68% |
| Total Other Income/Expenses | 6.23M | 1.66M | 1.04M | -5.75M | -1.59M | -745.00K |
| Income Before Tax | -123.46M | -106.48M | -95.40M | -35.85M | -29.86M | -28.98M |
| Income Before Tax Ratio | 0.00% | 0.00% | -38,160.80% | -8,357.34% | -574.13% | -272.69% |
| Income Tax Expense | 0.00 | -1.20M | 4.00K | 1.39M | 1.55M | 204.00K |
| Net Income | -123.46M | -105.28M | -95.41M | -37.24M | -31.40M | -28.98M |
| Net Income Ratio | 0.00% | 0.00% | -38,162.40% | -8,680.89% | -603.88% | -272.69% |
| EPS | -2.58 | -2.70 | -2.76 | -1.11 | -0.93 | -1.34 |
| EPS Diluted | -2.58 | -2.70 | -2.76 | -1.11 | -0.93 | -1.34 |
| Weighted Avg Shares Out | 47.78M | 38.93M | 34.56M | 33.66M | 33.66M | 21.59M |
| Weighted Avg Shares Out (Dil) | 47.78M | 38.93M | 34.56M | 33.66M | 33.66M | 21.59M |
BioAtla, Inc. (BCAB) CEO Jay Short on Q2 2022 Results - Earnings Call Transcript
BioAtla, Inc. (NASDAQ:BCAB ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors Jay Short - Chairman, CEO and Co-Founder Scott Smith - President Philippe Martin - Chief of Clinical Development...
BioAtla, Inc. (BCAB) Reports Q2 Loss, Lags Revenue Estimates
BioAtla, Inc. (BCAB) delivered earnings and revenue surprises of -10% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
BioAtla to Announce Second Quarter 2022 Financial Results and Provide Business Highlights on August 9, 2022
SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to...
BioAtla to Participate in 2022 Jefferies Global Healthcare Conference
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that Jay M. Short,...
BioAtla, Inc. (BCAB) CEO Jay Short on Q1 2022 Results - Earnings Call Transcript
BioAtla, Inc. (NASDAQ:BCAB ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors Jay Short - Chairman, CEO and Co-Founder Scott Smith - President Philippe Martin - Chief of Clinical Development...
BioAtla to Announce First Quarter 2022 Financial Results and Provide Business Highlights on May 4, 2022
SAN DIEGO, April 08, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody and other protein therapeutics, today announced that it plans to host a conference...
BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo® (nivolumab) for Treatment of Solid Tumors
SAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered into a clinical collaboration with Bristol Myers...
BioAtla Announces Private Placement of 2.7 Million Shares
SAN DIEGO, Sept. 29, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered into stock purchase agreements with a group of...
BioAtla Announces Second Quarter 2021 Financial Results And Provides Clinical Update
SAN DIEGO, Aug. 13, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced financial results for the second quarter of 2021 and provided an...
BioAtla Announces First Quarter 2021 Financial Results And Provides Business Update
SAN DIEGO, May 12, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced financial results for the first quarter of 2021 and provided an update...
Source: https://incomestatements.info
Category: Stock Reports